Pivotal results from TRIUMPH-2 showed retatrutide, an investigational triple hormone receptor agonist, delivered substantial weight loss and A1C improvements in obesity and type 2 diabetes. Findings from ACHIEVE-4, the largest and longest study of Foundayo in type 2 diabetes, reaffirmed its safety profile and suggested the potential to provide cardiovascular benefits. Lilly will unveil Phase 2 data for eloraTZP, our latest triple-acting medicine combining the selective amylin receptor agonist eloralintide and GIP/GLP-1 receptor agonist tirzepatide.
INDIANAPOLIS, Sept. 15, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), Mounjaro (tirzepatide) and Foundayo (orforglipron), will present new data across its cardiometabolic health portfolio at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) taking place September 28 to October 2, 2026 in Milan, Italy. These data, spanning multiple mechanisms and modalities, reflect Lilly's commitment to changing the course of cardiometabolic disease by expanding treatment choice today and raising the standard of care for tomorrow.
"More than a billion people worldwide are living with diabetes or obesity, and meeting their diverse needs requires multiple treatment options based on different mechanisms," said Kenneth Custer, Ph.D., executive vice president and president, Lilly Cardiometabolic Health. "We've built our portfolio with a goal of changing the course of the diabetes and obesity epidemics. At EASD 2026, we're showing what the next generation of innovation could deliver for patients, and how we intend to raise the bar for medicines of the future."
Lilly will also host an industry symposium, Changing the Course of Cardiometabolic Disease, on Monday, September 28 from 10:00 a.m. to 4:00 p.m. CEST, chaired by Prof. Rachel Batterham, senior vice president, medical innovation and external engagement, Lilly Cardiometabolic Health. Marking 150 years of Lilly innovation, the program will explore how obesity and type 2 diabetes can be treated from early stages of disease, with sessions on the emerging role of oral therapies and the next generation of mechanisms with the potential to redefine patient care.
Select Lilly Presentations at EASD 2026
Retatrutide Symposium | Wednesday, September 30, 2026 | 8:30 to 9:30 a.m. CEST
This EASD-sponsored symposium will present Phase 3 results for retatrutide, an investigational once-weekly GIP, GLP-1, and glucagon triple receptor agonist.
- TRIUMPH-2: Adults with obesity or overweight and type 2 diabetes taking retatrutide lost up to an average of 49.6 lbs (22.5 kg; 20.8%) and lowered their A1C by up to an average of 1.6% at 80 weeks.¹
Mounjaro (Tirzepatide) Symposium | Wednesday, September 30, 2026 | 8:30 to 9:30 a.m. CEST
This EASD-sponsored symposium will present results for Mounjaro (tirzepatide) in adults living with type 2 diabetes and established cardiovascular disease.
- SURPASS-CVOT: Mounjaro demonstrated non-inferiority vs. Trulicity with an 8% lower risk of MACE-3 events (HR: 0.92; 95.3% CI: 0.83 to 1.01), while delivering greater reductions in A1C and weight in adults with type 2 diabetes and established cardiovascular disease.²,³
EloraTZP Symposium | Wednesday, September 30, 2026 | 4:30 to 5:30 p.m. CEST
This EASD-sponsored symposium on amylins in diabetes will feature Phase 2 results for eloraTZP, an investigational combination of eloralintide and tirzepatide, in adults with obesity or overweight and type 2 diabetes.
Foundayo (Orforglipron) Symposium | Thursday, October 1, 2026 | 8:30 to 9:15 a.m. CEST
This EASD-sponsored symposium will present Phase 3 results for Foundayo (orforglipron) across the ACHIEVE type 2 diabetes program.
- ACHIEVE-4: Foundayo demonstrated non-inferiority versus insulin glargine, with a 16% lower risk of MACE-4 events (HR: 0.84; 95.0% CI: 0.59 to 1.20) and a 23% lower risk of MACE-3 events (HR: 0.77; 95.0% CI: 0.52 to 1.13), in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk.²
Foundayo (Orforglipron) Oral Presentations and Posters
- ACHIEVE-2/ACHIEVE-3 Time-to-Goal Analysis: Foundayo 17.2 mg helped adults with type 2 diabetes reach their A1C target and body weight loss goals faster than dapagliflozin and oral semaglutide 7 mg and 14 mg.⁴
- ATTAIN-1 Physical and Psychosocial Functioning: In adults with obesity or overweight and at least one weight-related medical problem, Foundayo improved both physical and psychosocial functioning versus placebo.
Zepbound and Mounjaro (Tirzepatide) Oral Presentations and Posters
- SURMOUNT-5 Exploratory Proteomic Findings: Zepbound 10 mg and 15 mg were associated with distinct changes in the plasma proteome compared with semaglutide 1.7 mg and 2.4 mg, offering early biological insight into the differences in cardiometabolic benefit observed between the two therapies in the head-to-head SURMOUNT-5 trial.
- SURPASS-EARLY Pre-Specified Analysis: Mounjaro improved markers of beta cell function and insulin sensitivity in early type 2 diabetes.
- Phase 4 T-RAM: Mounjaro helped adults with type 2 diabetes maintain glycemic control and was generally well-tolerated during Ramadan fasting.
EloraTZP Oral Presentations and Posters
- EloraTZP Phase 1 Results: Adding eloralintide 3 mg to tirzepatide 5 mg led to 17% weight loss over 16 weeks versus 10% with tirzepatide 5 mg alone in adults with obesity or overweight.¹
About Zepbound (Tirzepatide) Injection
Zepbound (tirzepatide) is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication. Zepbound tackles an underlying cause of excess weight. It reduces appetite and how much you eat. Zepbound is indicated for adults with obesity, or some adults who are overweight and also have at least one weight-related medical problem, to lose weight and keep it off. Additionally, Zepbound is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. Zepbound should be used with a reduced-calorie diet and increased physical activity.
About Mounjaro (Tirzepatide) Injection
Fig. 1 Overview of the pleiotropic effects of GIP and GLP-1 at the organ/tissue level, including pancreatic islets, CNS, adipose tissue, and gastrointestinal tract. Source: Eli Lilly Medical Information (free access).
Mounjaro (tirzepatide), the #1 prescribed branded type 2 diabetes medicine for adults in the U.S., is an injectable medicine for adults and children 10 years of age and older with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose). In adults with type 2 diabetes who are at high risk for cardiovascular events, Mounjaro is also indicated to lower the risk of major adverse cardiovascular (CV) events (MACE), including CV death, non-fatal heart attack, or non-fatal stroke. As the first and only FDA-approved GIP and GLP-1 receptor agonist, Mounjaro is a single molecule that activates the body's receptors for GIP and GLP-1.
About Foundayo (Orforglipron)
Foundayo (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems, to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake.² Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. In addition to chronic weight management, orforglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.
About Retatrutide
Retatrutide is an investigational once-weekly triple hormone receptor agonist. Retatrutide is a single molecule that activates the body's receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Lilly is studying retatrutide in several Phase 3 clinical trials to evaluate its potential efficacy and safety in obesity and overweight with at least one weight-related medical problem, type 2 diabetes, knee osteoarthritis, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease. Retatrutide is an investigational molecule that is legally available only to participants in Lilly's clinical trials.
About Eloralintide
Eloralintide is an investigational once-weekly, selective amylin receptor agonist previously known as LY3841136. Eloralintide has the potential to decrease calorie intake, and the effects are likely mediated by affecting satiety, or the feeling of fullness. Phase 3 trials of eloralintide for the treatment of obesity and in adults with obesity or overweight with or without type 2 diabetes are currently ongoing. Lilly also conducted a Phase 2 study (NCT06603571) evaluating eloralintide, alone or in combination, with tirzepatide for weight management in adults with obesity or overweight and type 2 diabetes.
Endnotes
- Data calculated using the efficacy estimand. The efficacy estimand represents efficacy had all randomized participants remained on study intervention (with possible dose interruptions and modifications) without initiating prohibited weight management treatments (and glycemic rescue therapy for glycemic endpoints only).
- Time to first event analysis using a Cox proportional hazard model. All data from randomization to the end of the study were included in the analysis.
- All measures were multiplicity-controlled for type 1 error except weight and A1C reduction.
- Results are based on median time.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn.
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995), including about Foundayo (orforglipron), retatrutide, eloralintide, and eloraTZP as potential treatments for adults with obesity and/or type 2 diabetes and the timeline for future readouts, presentations, and other milestones relating to Foundayo, retatrutide, eloralintide and eloraTZP and its clinical trials, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that product candidates will prove to be safe and effective treatments for relevant indications or receive regulatory approval or additional regulatory approvals, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Refer to:
- Niki Biro; [email protected] (Media)
- Michael Czapar; [email protected] (Investors)
View original content to download multimedia: PR Newswire
SOURCE Eli Lilly and Company